Neurogene Shares Tank After Adverse Event Linked to Early-Stage Rett Syndrome Gene Therapy

Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated at a lower dose and showed promising efficacy outcomes.